EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis

Ziying Zhou, Chenxi Zhao, Siyan Li, Xiaoyang Han, Jiangyi Zhu, Situ Xue, Zhuorong Li

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25063350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ziying Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China. Hauptthemen laut MEDLINE: Osteoporosis, Bone Density Conservation Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first-line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use of existing peptides and monoclonal antibodies are limited, and small-molecule bone formation–promoting drugs are urgently required. We established an I-9 synthesis route with high yield, simple operation, and low cost that was suitable for future large-scale production. I-9 administration promoted bone formation and increased bone mass in mice with low bone mass in an aged C57 mouse model. Our findings revealed a hitherto undescribed pathway involving the BMP2–ERK–ATF4 axis that promotes osteoblast differentiation; I-9 has favorable biosafety in mice. This study systematically investigated the efficacy, safety, and mechanism of I-9 for treating osteoporosis and positions this drug for preclinical research in the future. Thus, this study has promoted the development of small-molecule bone-promoting drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoporosisBone Density Conservation AgentsAgedMiceHumansAnimalsOsteogenesisPharmaceutical PreparationsPeptidesCell DifferentiationOsteoblastsActivating Transcription Factor 4Bone Morphogenetic Protein 2

Stichwörter der Autor:innen

6-methoxybenzofuranATF4BMP-2bone formationosteoblastosteoporosis

Substanzen

Pharmaceutical PreparationsBone Density Conservation AgentsPeptidesATF4 protein, humanActivating Transcription Factor 4BMP2 protein, humanBone Morphogenetic Protein 2

Autor:innen und Institutionen

  • Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Z., Zhao, C., Li, S., Han, X., Zhu, J., Xue, S., & Li, Z. (2024). BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063350

Vancouver

Zhou Z, Zhao C, Li S, Han X, Zhu J, Xue S, et al. BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063350

BibTeX
@article{Zhou2024,
  author = {Zhou, Ziying and Zhao, Chenxi and Li, Siyan and Han, Xiaoyang and Zhu, Jiangyi and Xue, Situ and Li, Zhuorong},
  title = {BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25063350}
}
Kostenlos starten →